How Artificial Intelligence (AI) May Improve Healthcare

Petra Schultz


Healthcare data are growing at an exponential rate, and technologies in the workplace are advancing rapidly. This session will address how artificial intelligence is making an impact in healthcare today and how emerging technologies may be applied in the future.

Learning Objectives:
After attending this lecture, students and healthcare professionals will be able to:
- Define artificial intelligence (AI) and cognitive systems
- Understand where AI may be applied to tackle problems in healthcare
- Discuss examples of successful AI technologies in the industry today and emerging technologies of the future
- Identify barriers to adoption and challenges of AI in healthcare

Target audience:
Medical, Nursing, Pharmacy, Public health, and Dental students & clinicians in practice. NOTE: A higher level presentation can be arranged/added with researchers in mind.

Aligns to:
For physicians and non-physicians, this lecture aligns to LCME and AGCME competencies of Medical Knowledge and Clinical Reasoning, Interpersonal and Communication Skills (AI/NLP).

For nursing, this lecture aligns to AACN Essential Core Competencies of Information and Technology, Academic-Practice Partnerships, Systems-based Practice, and Career-long Learning.

For pharmacists, this lecture supports learning objectives for ACPE Doctor of Pharmacy curriculum requirements for Clinical Sciences – Health Informatics and competencies for ASHP PGY1 Residencies and PGY2 Residencies in Pharmacy Informatics.

Conflict of Interest: Petra Schultz, PharmD is employed by IBM Watson Health which develops and markets products and services across the healthcare market.


Photo of Petra Schultz

Dr. Petra Schultz has 23 years of experience in healthcare, focused on clinical drug information, therapeutic policy management, and health information technology. In her current role, she works closely with marketing, communications, and sales enablement colleagues to infuse clinical perspective and the scientific evidence behind IBM Watson Health solutions into resources to support client-facing teams speak the value of Watson Health solutions.

In her previous role as Director of Product Management for Truven Health Analytics (now part of IBM Watson Health), Dr. Schultz led a team responsible for the delivery of the Micromedex Clinical Knowledge, Patient Connect, and 360 Care Insights solution portfolios. She led her team through integration into IBM and early phases of bringing cognitive services into Micromedex. Dr. Schultz previously held various positions across Truven, first within the Micromedex Editorial team then later in a client-facing role shaping and communicating the value proposition and messaging platform for Micromedex and leading the Micromedex Academic Program.

Prior to coming to Truven, Dr. Schultz practiced and held academic appointments in drug information and therapeutic policy management at the Medical University of South Carolina and the Mayo Clinic. She was responsible for instituting formal formulary management services and implementing and leading the first drug information service supporting clinicians across the Mayo Clinic Florida campus.

Petra received her Doctor of Pharmacy from the University of Florida, followed by completion of ASHP-accredited residencies in Pharmacy Practice and Drug Information Specialty Practice at University Medical Center (Jacksonville) and Shands Jacksonville, now a part of UF Health. Petra also has a Bachelor of Science in Marketing from Florida State University.

Requested 30 times

Lecture languages



AI ApplicationHealthcareMedical

Duration options

1 hour

Travel/delivery options

In-countryNo travel required: On DemandOn DemandOutside of country: Open for discussionRemote via video conference


United States

Lecture booking request

Thank you for your interest in hosting an IBM speaker. Please fill out the following form with as much detail as possible. An IBM representative will reach out to discuss your booking request. All guest lectures are subject to availability and agreements under this collaboration are not legally binding.